



Stabilis



Nitroglycerin



Kereskedelmi név

Angiopohl	Mexikó
Dauxona	Argentína
Enetege	Argentína
Gitrinil	Malaysia
Imectin	Ecuador
Netronal	Irán
Niglinar	Argentína
Nitracor	Lengyelország
Nitrocine	Egyesült Arab Emírségek, Irán, Malaysia, Nagy-Britannia
Nitroglycerin	Amerikai Egyesült Államok, Hollandia, Kanada, Mexikó, Norvégia, Svájc, Svédország, Szaúd-Arábiában
Nitrogray	Argentína, Peru
Nitroject	Kanada
Nitrolingual	Görögország, Németország
Nitronal	Franciaország, Irán, Románia, Svájc, Törökország, új-Zéland
Perlinganit	Ausztria, Finnország, Lengyelország, Luxemburg, Németország, Svájc, Törökország
Solinitrina	Spanyolország
Trinitrosan	Irán



Az oldatok stabilitása

		0,05 mg/ml	25°C		48			708
		0,05 mg/ml	25°C		48			1223
		0,05 mg/ml	35-37°C		48			708
		0,05 mg/ml	4°C		48			708
		0,05 mg/ml	4°C		48			1223
		0,09 mg/ml	25°C		24			621
		0,1 mg/ml	21°C		24			350
		0,2 & 0,4 mg/ml	18-27°C		28			1027

		0,2 & 0,4 mg/ml	5°C		28			1027
		0,05 mg/ml	25°C		48			708
		0,05 mg/ml	25°C		48			1223
		0,05 mg/ml	35-37°C		48			708
		0,05 mg/ml	4°C		48			708
		0,05 mg/ml	4°C		48			1223
		0,09 mg/ml	25°C		24			621
		0,2 & 0,4 mg/ml	18-27°C		28			1027
		0,2 & 0,4 mg/ml	5°C		28			1027
		0,656 mg/ml	25°C		24			1270
		1 mg/ml	23°C		24			192
	RL	0,2 & 0,4 mg/ml	18-27°C		28			1027
	RL	0,2 & 0,4 mg/ml	5°C		28			1027
		0,2 & 0,4 mg/ml	18-27°C		28			1027
		0,2 & 0,4 mg/ml	5°C		28			1027
	Ø	5 mg/ml	25°C		23			90
PE		0,01 mg/ml	22°C		24			1067
PE		0,01 mg/ml	4°C		24			1067
PE		0,06 mg/ml	20-25°C		48			1960
PE		0,09 mg/ml	25°C		24			621
PE		0,1 mg/ml	21°C		24			350
PE		0,01 mg/ml	22°C		24			1067
PE		0,01 mg/ml	4°C		24			1067
PE		0,06 mg/ml	20-25°C		48			1960
PE		0,09 mg/ml	25°C		24			621
PE		0,1 mg/ml	25°C		35			1980
POF		0,05 mg/ml	25°C		48			1223
POF		0,05 mg/ml	4°C		48			1223
POF		0,06 mg/ml	25°C		48			1522
POF		0,2 & 0,4 mg/ml	18-27°C		28			1027
POF		0,2 & 0,4 mg/ml	5°C		28			1027
POF		0,05 mg/ml	25°C		48			1223
POF		0,05 mg/ml	4°C		48			1223

POF	◆	0,06 mg/ml	25°C	☀	48	☑		1522
POF	◆	0,2 & 0,4 mg/ml	18-27°C	☀	28	◐		1027
POF	◆	0,2 & 0,4 mg/ml	5°C	☀/	28	◐		1027
POF	◆	0,42 mg/ml	25°C	☀	24	☑		2146
POF	RL	0,2 & 0,4 mg/ml	18-27°C	☀	28	◐		1027
POF	RL	0,2 & 0,4 mg/ml	5°C	☀/	28	◐		1027
POF	0.45	0,2 & 0,4 mg/ml	18-27°C	☀	28	◐		1027
POF	0.45	0,2 & 0,4 mg/ml	5°C	☀/	28	◐		1027
PP	◆	0.11 mg/ml	23-27°C	☀/	24	◐		3536
PP	◆	1 mg/ml	25°C	☀	24	☑		196
PP	∅	? mg/ml	-20°C	☀/	30	◐		554
PP	∅	? mg/ml	25°C	☀/	6	☑		554
PP	∅	? mg/ml	4°C	☀/	7	◐		554
PP	∅	5 mg/ml	25°C	☀/	23	☑		90



A keverékek stabilitása

☹	≈	[]	- +	☀?	🧬		⌚	📖
☹	▲	0,1 & 0,4 mg/ml	20°C-25°C	☀	Tirofiban : 50 µg/ml	4	☑	1603
☹	▲	0,1 mg/ml	25°C	☀	Bretylium tosilate : 10 mg/ml	48	☑	705
☹	▲	0,1 mg/ml	40°C	☀/	Bretylium tosilate : 10 mg/ml	48	☑	705
☹	▲	0,1 mg/ml	4°C	☀/	Bretylium tosilate : 10 mg/ml	7	◐	705
☹	▲	0,2 mg/ml	?	?	Nitroprusside sodium : 0,2 mg/ml Dobutamine hydrochloride : 2 mg/ml	24	☑	1109
☹	◆	0,2 mg/ml	20°C-25°C	☀	Labetalol hydrochloride : 1 mg/ml	4	☑	199
☹	◆	0,1 & 0,4 mg/ml	20°C-25°C	☀	Tirofiban : 50 µg/ml	4	☑	1603
☹	◆	0,4 mg/ml	22°C-23°C	☀	Milrinone lactate : 0,2 mg/ml	4	☑	813
☹	◆	0,1 mg/ml	25°C	☀	Bretylium tosilate : 10 mg/ml	48	☑	705
☹	◆	0,1 mg/ml	40°C	☀/	Bretylium tosilate : 10 mg/ml	48	☑	705
☹	◆	0,1 mg/ml	4°C	☀/	Bretylium tosilate : 10 mg/ml	7	◐	705



Stabilitást befolyásoló tényezők

					857
	PVC				380 1108 1113 1161 1166
	PVC				190 194 350 621 708 1223 1270 1353 1472 1960 1980 2324
	PP				3536
	EVA				2324



Kompatibilitás

		Nitroglycerin : 0.2 mg/ml Alteplase : 1 mg/ml		92
		Nitroglycerin : 0.4 mg/ml Alteplase : 0.5 mg/ml		240
		Nitroglycerin : 0.4 mg/ml Aminophylline : 1 mg/ml		1049
		Nitroglycerin : 0.4 mg/ml Aminophylline : 1 mg/ml		1049
		Nitroglycerin : 0.21 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
		Nitroglycerin : 0.21 mg/ml Amiodarone hydrochloride : 4 mg/ml		1036
		Nitroglycerin Amiodarone hydrochloride		3464
		Nitroglycerin : 1 mg/ml Amiodarone hydrochloride : 12,5 mg/ml		4119
		Nitroglycerin : 1 mg/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Nitroglycerin : 0.2 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Nitroglycerin : 1 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119

		Nitroglycerin : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Nitroglycerin : 0.4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Nitroglycerin : 0.2 mg/ml Argatroban : 1 mg/ml		1963
		Nitroglycerin : 0.4 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Nitroglycerin : 0.4 mg/ml Bivalirudin : 5 mg/ml		1713
		Nitroglycerin : 0.4 mg/ml Bretylum tosilate : 10 mg/ml		1049
		Nitroglycerin : 0.4 mg/ml Bretylum tosilate : 10 mg/ml		1049
		Nitroglycerin : 0,1 mg/ml Bretylum tosilate : 10 mg/ml		705
		Nitroglycerin : 0,1 mg/ml Bretylum tosilate : 10 mg/ml		705
		Nitroglycerin : 5 mg/ml Caffeine : 10 mg/ml		3964
		Nitroglycerin : 0.4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Nitroglycerin : 0.4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Nitroglycerin : 0.2 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Nitroglycerin : 0.4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Nitroglycerin : 0.4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Nitroglycerin : 0.2 mg/ml Cisatracurium besylate : 5 mg/ml		3823
		Nitroglycerin : 0.4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Nitroglycerin : 0,4 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Nitroglycerin : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Nitroglycerin Conivaptan		3715
		Nitroglycerin : 0.4 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Nitroglycerin : 0,032 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
		Nitroglycerin : 0.4 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Nitroglycerin : 0.4 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Nitroglycerin : 0.4 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Nitroglycerin : 0.24 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041

	Nitroglycerin : 0.4 mg/ml Dopamine hydrochloride : 0.8 mg/ml		1049
	Nitroglycerin : 0.4 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Nitroglycerin : 0.4 mg/ml Dopamine hydrochloride : 0.8 mg/ml		1049
	Nitroglycerin : 0,18 mg/ml Enalaprilate : 0,011 mg/ml		963
	Nitroglycerin : 0.09 mg/ml Enalaprilate : 0.0125 mg/ml		1703
	Nitroglycerin : 0.4 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Nitroglycerin Eptifibatide		3934
	Nitroglycerin : 0.2 mg/ml Esmolol hydrochloride : 10 mg/ml		3823
	Nitroglycerin : 0.2 mg/ml Esmolol hydrochloride : 10 mg/ml		3823
	Nitroglycerin : 0,085 mg/ml Famotidine		397
	Nitroglycerin : 0.8 mg/ml Famotidine : 0.2 mg/ml		398
	Nitroglycerin : 0.4 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Nitroglycerin : 0.4 mg/ml Fentanyl citrate : 50 µg/ml		314
	Nitroglycerin : 0,2 mg/ml Fentanyl citrate : 50 µg/ml		63
	Nitroglycerin : 0.4 mg/ml Fosfomycin : 30 mg/ml		4055
	Nitroglycerin Furosemide		3465
	Nitroglycerin : 0.4 mg/ml Furosemide : 10 mg/ml		314
	Nitroglycerin : 0.4 mg/ml		301
	Nitroglycerin : 0,2 mg/ml Fluconazole : 2 mg/ml		255
	Nitroglycerin : 0.4 mg/ml Fosfomycin : 30 mg/ml		4055
	Nitroglycerin : 0.4 mg/ml Furosemide : 0.67 mg/ml		1049
	Nitroglycerin : 0.4 mg/ml Furosemide : 0.67 mg/ml		1049
	Nitroglycerin : 0.2 mg/ml Furosemide : 10 mg/ml		3823
	Nitroglycerin : 0.2 mg/ml Furosemide : 10 mg/ml		3134
	 Nitroglycerin : 1 mg/ml Furosemide : 10 mg/ml		3210
	Nitroglycerin : 0.2 mg/ml Furosemide : 10 mg/ml		3823

		Nitroglycerin : 0.2 mg/ml Haloperidol lactate : 0.5 mg/ml		3823
		Nitroglycerin : 0.4 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
		Nitroglycerin : 0.2 mg/ml Haloperidol lactate : 0.5 mg/ml		3823
		Nitroglycerin : 1,6 >> 3,25 mg/ml Heparin sodium : 100 UI/ml		295
		Nitroglycerin : 0.4 mg/ml Heparin sodium : 100 UI/ml		314
		Nitroglycerin : 0.2 mg/ml Heparin sodium : 500 UI/ml		3823
		Nitroglycerin : 0.2 mg/ml Heparin sodium : 500 UI/ml		3823
		Nitroglycerin : 0.4 mg/ml Hydralazine hydrochloride : 1 mg/ml		1049
		Nitroglycerin Hydroxocobalamin		3932
		Nitroglycerin : 0.2 mg/ml Insulin : 2 UI/ml		3823
		Nitroglycerin : 0,5 & 1 mg/ml Insulin aspart : 1 UI/ml		1508
		Nitroglycerin : 0.4 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Nitroglycerin : 0.4 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Nitroglycerin : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Nitroglycerin : 0.2 mg/ml Labetalol hydrochloride : 4 mg/ml		3823
		Nitroglycerin : 0.4 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Nitroglycerin : 5 mg/ml	RL	4603
		Nitroglycerin : 0,5 & 1 mg/ml Insulin aspart : 1 UI/ml		1508
		Nitroglycerin : 0.4 mg/ml		1415
		Nitroglycerin : 0.2 mg/ml Heparin sodium : 50 UI/ml		317
		Nitroglycerin : 0.4 mg/ml Hetastarch : 60 mg/ml		1721
		Nitroglycerin : 0.4 mg/ml Hydralazine hydrochloride : 1 mg/ml		1049
		Nitroglycerin : 0.4 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Nitroglycerin : 0,4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Nitroglycerin : 0.2 mg/ml Insulin : 2 UI/ml		3823
		Nitroglycerin : 0.2 mg/ml Insulin : 1 UI/ml		295
		Nitroglycerin : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109

		Nitroglycerin : 0.2 mg/ml Labetalol hydrochloride : 1 mg/ml		199
		Nitroglycerin : 0.2 mg/ml Labetalol hydrochloride : 5 mg/ml		295
		Nitroglycerin : 0.4 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Nitroglycerin : 0.2 mg/ml Labetalol hydrochloride : 4 mg/ml		3823
		Nitroglycerin : 5 mg/ml Levofloxacin : 5 mg/ml		1072
		Nitroglycerin : 0,1 mg/ml Levosimendan : 0,025 & 0,05 mg/ml		4571
		Nitroglycerin Lidocaine hydrochloride		5060
		Nitroglycerin : 0.4 mg/ml Lidocaine hydrochloride : 4 mg/ml		1049
		Nitroglycerin : 0.4 mg/ml Lidocaine hydrochloride : 4 mg/ml		1049
		Nitroglycerin : 0.4 mg/ml Linezolid : 2 mg/ml		1925
		Nitroglycerin : 0.4 mg/ml Lorazepam : 0.5 mg/ml		314
		Nitroglycerin : 5 mg/ml Meropenem : 50 mg/ml		4319
		Nitroglycerin : 0.2 mg/ml Metoprolol tartrate : 1 mg/ml		2346
		Nitroglycerin : 0.4 mg/ml Miconazole : 1.5 mg/ml		2108
		Nitroglycerin : 0.2 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3823
		Nitroglycerin : 0.2 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3823
		Nitroglycerin : 0,2 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Nitroglycerin : 0.2 mg/ml Midazolam hydrochloride : 1 mg/ml		295
		Nitroglycerin : 0.4 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Nitroglycerin : 0.4 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Nitroglycerin : 1.6 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Nitroglycerin : 0.4 mg/ml Morphine sulfate : 2 mg/ml		314
		Nitroglycerin : 5 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Nitroglycerin : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Nitroglycerin : 0.4 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Nitroglycerin : 0.4 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314

	Nitroglycerin : 0.4 mg/ml Oritavancin : 0.8 >> 2 mg/ml		3152
	Nitroglycerin : 0.4 mg/ml Pancuronium bromide : 0.05 mg/ml		402
	Nitroglycerin Pantoprazole sodium		2090
	Nitroglycerin : 0.1 >> 0.4 mg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
	Nitroglycerin : 5 mg/ml Paracetamol : 10 mg/ml		4742
	Nitroglycerin : 0.4 mg/ml Phenytoin sodium : 1 mg/ml		1049
	Nitroglycerin : 0.4 mg/ml Phenytoin sodium : 1 mg/ml		1049
	Nitroglycerin : 0.4 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Nitroglycerin : 0.2 mg/ml Potassium chloride : 10 mEq/l		3823
	Nitroglycerin : 0.2 mg/ml Potassium chloride : 10 mEq/l		3823
	Nitroglycerin : 0.4 mg/ml Propofol : 10 mg/ml		300
	Nitroglycerin : 0.4 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
	Nitroglycerin : 0,2 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396
	Nitroglycerin : 0.4 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Nitroglycerin : 5 mg/ml Salbutamol sulfate : 1 mg/ml		3216
	Nitroglycerin : 0.2 mg/ml Sodium bicarbonate : 84 mg/ml		3823
	Nitroglycerin : 0.2 mg/ml Sodium bicarbonate : 84 mg/ml		3212
	Nitroglycerin Sodium bicarbonate		3466
	Nitroglycerin : 0.2 mg/ml Streptokinase : 30000 UI/ml		92
	Nitroglycerin : 5 mg/ml Sugammadex : 100 mg/ml		3372
	Nitroglycerin : 0,4 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Nitroglycerin : 0,1 mg/ml Tacrolimus : 1000 µg/ml		479
	Nitroglycerin : 0.4 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Nitroglycerin : 0.2 mg/ml Theophylline : 4 mg/ml		317
	Nitroglycerin : 0.2 mg/ml Thiopental sodium : 60 mg/ml		3823
	Nitroglycerin : 0.4 mg/ml Thiopental sodium : 25 mg/ml		314

		Nitroglycerin : 5 mg/ml Thiopental sodium : 25 mg/ml		3767
		Nitroglycerin : 0.2 mg/ml Thiopental sodium : 60 mg/ml		3823
		Nitroglycerin : 0,1 & 0,4 mg/ml Tirofiban : 50 µg/ml		1603
		Nitroglycerin : 0.2 mg/ml Tirofiban : 250 µg/ml		3823
		Nitroglycerin : 0,1 & 0,4 mg/ml Tirofiban : 50 µg/ml		1603
		Nitroglycerin Tirofiban		1512
		Nitroglycerin : 0.2 mg/ml Tirofiban : 250 µg/ml		3823
		Nitroglycerin : 0.2 mg/ml Urapidil : 5 mg/ml		3823
		Nitroglycerin : 0.2 mg/ml Urapidil : 5 mg/ml		3823
		Nitroglycerin : 0.2 mg/ml Vasopressin : 2 & 4 UI/ml		1801
		Nitroglycerin : 0.4 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Nitroglycerin : 0.4 mg/ml Vecuronium bromide : 1 mg/ml		314
		Nitroglycerin : 0.1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Nitroglycerin : 0.1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Nitroglycerin : 0,4 mg/ml Warfarin sodium : 2 mg/ml		315



Az alkalmazás módja



Irodalom

	Type	publikáció
59	Napló	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Napló	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
90	Napló	Driver PS, Jarvi EJ, Gratzner PL. Stability of nitroglycerin concentrate for injection stored in plastic syringes. Am J Hosp Pharm 1993 ; 50: 2561-2563.

92	Napló	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Napló	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
176	Napló	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
190	Napló	Lee MG. Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets. Am J Hosp Pharm 1986 ; 43: 1945-1950.
192	Napló	Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419.
194	Napló	Loucas SP, Maager P, Mehl B, Loucas ER. Effect of vehicle ionic strength on sorption of nitroglycerin to a polyvinyl chloride administration set. Am J Hosp Pharm 1990 ; 47: 1559-1562.
196	Napló	Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207.
198	Napló	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Napló	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
240	Napló	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
255	Napló	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
295	Napló	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Napló	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Napló	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.

317	Napló	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
350	Napló	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
380	Napló	Grillo JA, Gonzalez ER, Ramaiya A, Karnes HT, Wells B. Chemical compatibility of inotropic and vasoactive agents delivered via a multiple line infusion system. Crit Care Med 1995 ; 23: 1061-1066.
396	Napló	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
397	Napló	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Napló	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Napló	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
403	Napló	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
479	Napló	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
524	Napló	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
554	Napló	Speaker TJ, Turco SJ, Nardone DA, Miripol JE. A study of the interaction of selected drugs and plastic syringes. J Parenter Sci Technol 1991 ; 45: 212-217.
621	Napló	Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER. Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. Am J Hosp Pharm 1982 ; 39: 1018-1021.
705	Napló	Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylum tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187.
708	Napló	Baaske DM, Amann AH, Wagenknecht DM, Mooers M, Carter JE, Hoyt HJ, Stoll RG. Nitroglycerin compatibility with intravenous fluid filters containers, and administration sets. Am J Hosp Pharm 1980 ; 37: 201-205.
813	Napló	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
857	Napló	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a "treated" inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.

921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
963	Napló	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1027	Napló	Wagenknecht DM, Baaske DM, Alam AS, Carter JE, Shah J. Stability of nitroglycerin solutions in polyolefin and glass containers. Am J Hosp Pharm 1984 ; 41: 1807-1811.
1036	Napló	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Napló	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	Napló	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1057	Napló	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1067	Napló	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1072	Napló	Saltmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1108	Napló	Dasta JF, Jacobi J, Wu LS, Sokoloski T, Beckley P, Reilley TE, Howie MB. Loss of nitroglycerin to cardiopulmonary bypass apparatus. Crit Care Med 1983 ; 11: 50-52.
1109	Napló	Horror JC, Digregorio J, Barbieri EJ, Rupp E. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med 1990 ; 18: 858-861.
1113	Napló	Tracy TS, Bowman L, Black CD. Nitroglycerin delivery through a polyethylene-lined intravenous administration set. Am J Hosp Pharm 1989 ; 46: 2031-2035.
1161	Napló	Allwood MC. Sorption of parenteral nitrates during administration with a syringe pump and extension set. Int J Pharm 1987 ; 39: 183-188.
1166	Napló	Sokoloski TD, Wu CC, Burkman AM. Rapid adsorptive loss of nitroglycerin from aqueous solution to plastic. Int J Pharm 1980 ; 6: 63-76.
1223	Napló	Amann AH, Baaske DM, Wagenknecht DM. Plastic IV container for nitroglycerin. Am J Hosp Pharm 1980 ; 37: 618.
1270	Napló	Mathot F, Bonnard J, Han P, Bosly J. IV infusion of glyceryl trinitrate. Study of the sorption on various plastic containers. J Pharm Belg 1980 ; 35: 389-393.
1353	Napló	Nix DE, Tharpe WN, Francisco GE. Effects of presaturation on nitroglycerin delivery by polyvinyl chloride infusion sets. Am J Hosp Pharm 1984 ; 41: 1835-1837.


1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1472	Napló	Salomies HEM, Heinonen RM, Toppila MAI. Sorpitive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags). Int J Pharm 1994 ; 110: 197-201.
1508	Napló	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratórium	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1522	Laboratórium	Macoflex N® Maco Pharma 2001
1603	Napló	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1703	Napló	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Napló	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Napló	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Napló	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Napló	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1902	Napló	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1960	Napló	Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C. Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers. J Pharm Biomed Anal 2005 ; 37: 259-264.
1963	Napló	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.

1980	Napló	Hansen HC, Spillum A. Loss of nitroglycerin during passage through two different infusion sets. Act Pharm Nord 1991 ; 3, 3: 131-136.
2018	Napló	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2090	Napló	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Napló	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Napló	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2146	Napló	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2324	Napló	Treleano A, Wolz G, Brandsch R, Welle F. Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application Int J Pharm 2009 ; 369, 1-2 : 30-37
2346	Napló	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3012	Napló	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3134	Napló	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemda en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Napló	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3210	Napló	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	Napló	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Napló	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3372	Napló	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3408	Napló	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.


3464	Napló	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Napló	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Napló	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3536	Napló	McCluskey S V, Vu N, Rueter J. Stability of Nitroglycerin 100 mcg/mL Stored in Polypropylene Syringes Int J Pharm Compound 2013 ; 17, 6: 515-519
3715	Napló	Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535
3766	Napló	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Napló	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Napló	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Napló	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	poszter	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poszter	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poszter	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratórium	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Laboratórium	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3964	Napló	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Napló	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	poszter	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004

4145	Napló	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Napló	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Napló	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Napló	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	Napló	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4571	Laboratórium	Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics Orion Pharma 2010
4603	Napló	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Napló	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Napló	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
5060	Laboratórium	Lidocaine Hydrochloride Injection B.P. 1.0% w/v - Summary of Product Characteristics Updated 09-Nov-2023 ADVANZ Pharma 2023

Stabilis



Nitroglycerin



Stabilitása gyógyszerészeti készítmények

		300 mg Nitrol 2% ®	vazelin >> 150 g	23-27°C		365		3892



Irodalom

	Type	publikáció
3892	Napló	Friciu M, Chefson A, Leclair G. Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions Can J Hosp Pharm 2016 ; 69, 4 : 329-333.



Szótár

	Értágító		Injekció
	Kereskedelmi név		Az oldatok stabilitása
	Csomagolás		Molekula
	Koncentráció		Hőmérséklet
	Tárolás		A stabilitás időtartama
	biohasonló		ellentmondó adatok
	Irodalom		Üveg
	0,9% nátrium-klorid		Fénytől védve tartandó
	Óra		Nincs meghatározva
	Fény		Nap
	5% glükóz	RL	Ringer-laktát oldat
	0,45% nátrium-klorid		Egy sem
	Polietilén		Poliolefin
	fecskendő polipropilén		A keverékek stabilitása
	Oldószer		Vegyület
	Stabilitást befolyásoló tényezők		Szűrés
	Előidéző		Adszorpció
	Poli(vinilklorid)		Abszorpció
	Polipropilén		Etilén-vinilacetát
	Kompatibilitás		Csapadék 12 óra múlva
	Összeegyeztethetetlen		Injekcióhoz való víz
	Összeegyeztethető		Zavarosság egy órán belül
	Azonnali csapadék		Zavarosság 4 óra alatt
	Parenterális táplálás (lipid-mentes)		Kémiai instabilitás
	Színváltozás		Csapadék 4 óra után
	Szubvizuális összeférhetetlenség		Parenterális táplálás (lipid)
	Gázbuborékok előállítása		egyedi oldószer
	Azonnali zavarosság		Meghatározatlan összeférhetetlenség
	Csapadék 8 óra után		Csapadék 24 óra múlva
	Az alkalmazás módja		Intravénás

 Intravénás infúzió	 Irodalom
 kenőcs	 Stabilitása gyógyszerészeti készítmények
 Origine	 segédanyag
 kenőcs	 Szótár